INNEXIS takes over the Life Science Campus Kundl from Novartis
30 employees are changing employers
Advertisement
INNEXIS Holding GmbH & Co. KG plans to acquire the Life Science Campus in Kundl, Austria, from the internationally active biotechnology and pharmaceutical company Novartis. This transaction will allow Novartis Austria to focus on its core business, particularly the research, development, and manufacture of innovative medicines.
“The acquisition of such a prosperous and long-established Pharma & Life Science Park as the one in Kundl is a milestone in our company’s development. We are very pleased that Novartis has placed its trust in us to operate and further develop the site in the best interests of the companies based there, the employees, and the region,” said Dr. Martin Egger, CEO of the INNEXIS Group. “INNEXIS specializes in supporting the pharmaceutical and biotechnology companies at our sites by taking over site management for our clients and supporting them with specialized solutions in the areas of engineering and logistics—so they can focus on their core business.”
In Kundl, INNEXIS plans to take over an area of approximately 264,000 m² comprising over 100 buildings, as well as the infrastructure and services. The research and production facilities themselves will remain the property of Novartis. Roland Gander, Managing Director of the Kundl/Schaftenau Campus, explained the strategic decision: “We have concluded that transferring the management of the Life Science Campus Kundl to a professional industrial park operator will better maximize and further develop the site’s economic potential and facilitate the establishment of new companies.”
For the majority of the approximately 850 employees at the Kundl site, nothing will change as a result of the takeover, as Novartis will continue to operate its core activities on the campus. The plan is for 30 employees from campus management to transfer to the INNEXIS Group with the same duties and responsibilities.
As the new owner and operator, INNEXIS plans to further develop the site. On the one hand, this involves attracting additional companies, as production buildings, offices, and vacant spaces are available for leasing.
“On the other hand, it is at the core of our corporate philosophy to ensure that the energy supply for our life science parks is sustainable and future-proof. Anyone who wants to reconcile security of supply, regulatory requirements, and decarbonization needs resilient and innovative infrastructure—and we will drive this forward in Kundl as well,” said Dr. Martin Egger.
The transaction is scheduled to take effect on January 1, 2027. The agreement is still subject to the fulfillment of the customary closing conditions and the receipt of the necessary regulatory approvals, including antitrust clearance in Austria.
Other news from the department business & finance
